MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)*
Organization & Developments: Vanda
Parents
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)*
Children
*Insomnia Drug in Trials
*Licensed for $500,000 from Bristol Meyers Sqibb (Insomnia), Novartis (Schizophrenia)
*Schizophrenia Drug in Trials
*Strategy is to develop drugs abondoned by others
2017: Vanda Pharmaceuticals Keeps Chugging Along - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
2018: Revisiting Vanda Pharmaceuticals_seekingalpha.com
2018: Vanda Pharmaceuticals: IOMachine Says This Is A Buy_seekingalpha.com
2019: Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
2022: Vanda Pharmaceuticals (VNDA) Investor Presentation -Slideshow_ seekingalpha.com
2022: Vanda Pharmaceuticals: What The Recent Partnership Entails_ seekingalpha.com
2022: Vanda: Can The Company Turn Around?_ seekingalpha.com
2022: Vanda: VPO-227 Advancement Signals More Upsides_seekingalpha.com
2023: Vanda Pharmaceuticals: FDA Approvals On Deck In 2024 Makes This A Must Watch_ seekingalpha.com
2023: Vanda Pharmaceuticals: Value In The Biotech Space
2024: FDA explains why it rejected Vanda's insomnia application as company faces takeover bid
2024: Vanda Pharmaceuticals Secures FDA Orphan Drug Status for Novel Blood Cancer Treatment VGT-1849A
2024: Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
2024: Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
2024: Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
2024: Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges
2024: Vanda, after rejecting Future Pak offer, gets $466M takeout bid from Cycle Pharma
2025: D.C.-based Vanda gets FDA nod for motion-sickness treatment
2025: Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement
2026: Vanda Pharmaceuticals’ stock tumbles after $220M loss
Jumps
*Key People: Vanda
Finance & Acquisition: Vanda